Monday, March 19, 2012

Avanir Pharmaceuticals, Inc. (AVNR) Appoints Mr. Rohan Palekar to Senior VP and CCO

Today, Avanir Pharmaceuticals announced that the company has appointed Rohan Palekar to the position of senior vice president and chief commercial officer. In his new role, Mr. Palekar will lead all of the company’s commercial activities.

“I am excited to be joining the Avanir team and working with this talented group to help make NUEDEXTA available to patients and physicians worldwide,” said Mr. Palekar. “The growth opportunity that lies ahead for Avanir is incredible and I look forward to the chance to positively affect the lives of patients suffering from pseudobulbar affect and other CNS disorders.”

Mr. Palekar has over 20 years of experience in the biopharmaceutical industry and has worked with notable brands including Remicade® and Stelara®. Mr. Palekar’s most recent commercial leadership role was as CCO for Medivation, where he oversaw all commercial activities, CMC & manufacturing, and public relations functions. Prior to his tenure at Medivation, Mr. Palekar spent over 16 years at Johnson & Johnson in various senior commercial and strategic management roles. He also recently served as vice president of sales & marketing at Centocor, where he successfully launched two new indications for Remicade.

Prior to these positions, Mr. Palekar held a position as worldwide vice president of immunology and held marketing leadership roles at McNeil Consumer and Specialty Pharmaceuticals. Mr. Palekar earned his MBA from the Amos Tuck School of Business Administration Dartmouth College and his BA/BS in Law and Accounting from the University of Bombay.

“Rohan has an outstanding track record of success in biopharmaceutical sales and marketing,” said Keith A. Katkin, president and CEO of Avanir. “I am delighted that we were able to attract someone of Rohan’s caliber to spearhead our global commercial activities. His comprehensive background in healthcare sales and marketing, new product planning and strategic analysis, as well as his leadership capabilities, will be pivotal to the continued commercial success of Avanir.”


About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html